


Invitation

*Benefit Concert
and
Welcome Reception*



Residenz Munich

Schubert

Symphony No. 5 B-dur, D 485

Symphony No. 8 C-dur, D 944

*and the Symphony Orchestra of the
„Bayerischer Rundfunk“*

conducted by

Riccardo Muti

for the benefit of the

„Bayerische Kinderhilfe Rumänien e.V.“

Saturday, March 28, 1998 at 7:30 p.m.

Location:

Residenz
– Herkulessaal –

Welcome Reception at the

Residenz
– Kaisersaal –



Transplantation of Hematopoiesis
from the Bench to the Bedside



Graft-versus-Host and Graft-versus-Leukemia Reactions 1998

Opening / Welcome

Morning
8.15 h

D. Seidel
Medical Director Klinikum Grosshadern

H.-G. Afting
Scientific Director GSF – National Research
Center for Environment and Health

H. J. Kolb
Cooperative Group for Hematopoietic
Cell Transplantation

Peptides – Antigens – Vaccines

8.30 h **H. G. Rammensee, Tübingen**
Antigen presentation by MHC molecules

8.50 h **U. Koszinowski, München**
Immunomodulation by Cytomegalovirus

9.10 h **P. K. Srivastava, Farmington**
HSP-peptide complexes as the basis of a
new generation of vaccines against cancer
and infectious diseases

Discussants:

9.30 h **E. Goulmy, Leiden**
Minor H peptides as ingredients for adoptive
immunotherapy of relapsed leukemia

9.40 h **B. Seliger, Mainz**
CTL-mediated immune recognition of
tumors: Nothing without proper class I
processing and presentation

9.50 h **G. Multhoff, München**
HSP 70 – a stimulatory signal for NK
proliferation and cytotoxicity against
cancer cells

10.00 h Panel-Discussion

10.20 h Coffee-Break

Adoptive Immunotherapy

Morning
10.40 h

J. Ferrara, Boston
Modulation of cytokines in GvH and

Discussants:

11.00 h **P. Fisch, Tübingen**
Recognition of haematopoietic tumors
by cytotoxic human T cells is controlled
by killer inhibitory receptors

11.10 h **R. Handgretinger, Tübingen**
Isolation of anti-leukemic effector cells
and their potential role in posttransplant
immunotherapy

11.20 h **D. Bunjes, Ulm**
Phenotype and specificity of effector cells
in donor lymphocyte transfusions

11.30 h **M. Lawler, Dublin**
Molecular monitoring of chimerism

11.40 h **F. Keil, Wien**
The role of chimerism in GvL

11.50 h **J. F. Apperley, London**
Dose escalation of donor leukocytes
management of relapsed CML

12.00 h **H. Einsele, Tübingen**
Adoptive immunotherapy of viral infections

12.10 h Panel-Discussion

12.30 h Lunch Break

Tolerance

Afternoon

13.30 h

Y. Reisner, Tel Aviv

Induction of transplantation tolerance by stem cells

13.50 h

M. G. Roncarolo, Torino

IL-10 and tolerance

14.10 h

S. Ildstad, Pittsburgh

Graft facilitating cells—from bench to bedside with prospects for tolerance

Discussants:

14.30 h

R. Storb, Seattle

Induction of mixed hematopoietic chimerism

14.40 h

D. W. van Bekkum, Leiden

Tolerance in autoimmune disease by auto- or allografting?

14.50 h

R. K. Burt, Chicago

Bone marrow transplantation for autoimmune disease

15.00 h

Panel-Discussion

15.20 h

Coffee-Break

Immune Activation and Gene Therapy

Afternoon

15.40 h

M. Roscrow, München

Vaccination with stimulated peptide pulsed DC protects against leukemia, but induces autoimmune disease

15.55 h

D. Dilloo, Düsseldorf

CD40L as a costimulatory molecule for the generation of a leukemia vaccine

16.10 h

C. Bordignon, Milano

HSV-Tk gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

16.25 h

P. Tiberghien, Besancon

Modulation of post-transplantation alloreactivity by the use of HSV-Tk expressing T-cells: experimental and clinical findings

Discussants:

16.40 h

D. Niederwieser, Innsbruck

Functional characterization of Ph1-positive dendritic cells

16.50 h

M. Hallek, München

CD40L-activated lymphoma cells for autologous vaccination of chronic lymphocytic leukemia

17.00 h

B. Gramatzki, Erlangen

Targeted therapy with monoclonal antibodies: Specific interaction with tumor cells

17.10 h

H. Lindhofer, München

The role of accessory cells in tumor immunotherapy by inact bispecific antibodies

17.20 h

G. Jung, München

Bispecific antibodies for T-cell activation against glioma and lymphoma cells

17.30 h

Panel-Discussion

17.50 h

Summary:

J. M. Goldman

This symposium would not have been possible without the generous support of:

Bayer AG, Geschäftsbereich Pharma
51368 Leverkusen

AMGEN GmbH
Riesstr. 25, 80992 München

Rhône-Poulenc Rorer
Nattermannallee 1, 50829 Köln

Zeneca GmbH
Otto-Hahn-Straße, 68723 Plankstadt

Fresenius AG,
61343 Bad Homburg

medac GmbH
Fehlandtstr. 3, 20354 Hamburg

Biotest Pharma GmbH
Landsteinerstr. 5, 63303 Dreieich

Institut Mérioux Transplant GmbH
Paul-Ehrlich-Str. 1, 69181 Leimen

Novartis Pharma GmbH
Roonstr. 25, 90429 Nürnberg

GlaxoWellcome GmbH & Co
Alsterufer 1, 20354 Hamburg

Hoffmann-La Roche AG
79630 Grenzach-Wyhlen

NeXstar Pharmaceuticals GmbH
Fraunhoferstr. 22, 82152 Martinsried

Baxter Deutschland GmbH
Edisonstr. 3-4, 85716 Unterschleißheim

SmithKline Beecham Pharma GmbH
Leopoldstr. 175, 80804 München

Bristol Arzneimittel GmbH
Volkartstr. 175, 80804 München

MSD Sharp & Dohme GmbH
Lindenplatz 1, 85540 Haar

Pharmacia & Upjohn GmbH
91051 Erlangen

Hoechst Marion Roussel
Königsteiner Str. 10, 65812 Bad Soden am Ts.

Astra GmbH, 22876 Wedel

Lederle Arzneimittel GmbH & Co
Schleibrüggenkamp 15, 48159 Münster

Pfizer GmbH
Pfizerstr. 1, 76139 Karlsruhe

Heumann Pharma GmbH
Heideloffstr. 18-28, 90478 Nürnberg

Chiron GmbH
Am Schimmersfeld 5, 40880 Ratingen